Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer.

Reynisdottir I, Arason A, Einarsdottir BO, Gunnarsson H, Staaf J, Vallon-Christersson J, Jonsson G, Ringnér M, Agnarsson BA, Olafsdottir K, Fagerholm R, Einarsdottir T, Johannesdottir G, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB.

Cancer Med. 2013 Aug;2(4):437-46. doi: 10.1002/cam4.88. Epub 2013 May 22.

2.

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.

Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adélaïde J, Baudelet E, Esteyriès S, Wicinski J, Audebert S, Charafe-Jauffret E, Jacquemier J, Lopez M, Borg JP, Sotiriou C, Popovici C, Bertucci F, Birnbaum D, Chaffanet M, Ginestier C.

EMBO Mol Med. 2011 Mar;3(3):153-66. doi: 10.1002/emmm.201100121. Epub 2011 Feb 15. Erratum in: EMBO Mol Med. 2011 Mar;3(3). doi:10.1002/emmm.201000121.

3.

Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors.

Bazarov AV, Yaswen P.

Breast Cancer Res. 2011 May 25;13(3):308. doi: 10.1186/bcr2873.

4.

High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.

Karlsson E, Waltersson MA, Bostner J, Pérez-Tenorio G, Olsson B, Hallbeck AL, Stål O.

Genes Chromosomes Cancer. 2011 Oct;50(10):775-87. doi: 10.1002/gcc.20900. Epub 2011 Jul 11.

PMID:
21748818
5.

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6.

6.

Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.

Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M, Shen K.

PLoS One. 2013 Aug 26;8(8):e72053. doi: 10.1371/journal.pone.0072053. eCollection 2013.

7.

Integrated profiling of basal and luminal breast cancers.

Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M.

Cancer Res. 2007 Dec 15;67(24):11565-75.

8.

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.

9.

ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.

Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, Chin SF, Hurtado A, Bruna A, Ali HR, Greenwood W, Dunning MJ, Samarajiwa S, Menon S, Rueda OM, Lynch AG, McKinney S, Ellis IO, Eaves CJ, Carroll JS, Curtis C, Aparicio S, Caldas C.

EMBO Mol Med. 2011 Mar;3(3):167-80. doi: 10.1002/emmm.201100122. Epub 2011 Feb 18.

10.

Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.

Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, Raynaud S, Charafe-Jauffret E, Jacquemier J, Spicuglia S, de The H, Viens P, Bertucci F, Birnbaum D, Chaffanet M.

PLoS One. 2014 Jan 9;9(1):e81843. doi: 10.1371/journal.pone.0081843. eCollection 2014.

11.

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.

Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

Breast Cancer Res Treat. 2009 Feb;113(3):457-66. doi: 10.1007/s10549-008-9964-x. Epub 2008 Mar 14.

PMID:
18340528
12.

EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.

Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JF, Nicholson RI, Sutherland RL.

Oncogene. 1998 Aug 27;17(8):1053-9.

13.

Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.

Burandt E, Jens G, Holst F, Jänicke F, Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R, Sauter G, Lebeau A.

Breast Cancer Res Treat. 2013 Feb;137(3):745-53. doi: 10.1007/s10549-013-2406-4. Epub 2013 Jan 16.

PMID:
23322234
14.

ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer.

Ma F, Bi L, Yang G, Zhang M, Liu C, Zhao Y, Wang Y, Wang J, Bai Y, Zhang Y.

Oncol Rep. 2014 Sep;32(3):1071-7. doi: 10.3892/or.2014.3313. Epub 2014 Jul 7.

PMID:
25017610
15.

Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis.

Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG.

Oncogene. 2009 Apr 30;28(17):1892-903. doi: 10.1038/onc.2009.34. Epub 2009 Mar 30.

16.

Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.

Holm K, Staaf J, Jönsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringnér M, Borg A.

Breast Cancer Res Treat. 2012 Jun;133(2):583-94. doi: 10.1007/s10549-011-1817-3. Epub 2011 Oct 16.

PMID:
22002566
17.

miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.

Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.

Endocr Relat Cancer. 2013 Feb 18;20(1):91-102. doi: 10.1530/ERC-12-0207. Print 2013 Feb.

18.

Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C.

Cancer Res. 1997 Oct 1;57(19):4360-7.

19.

Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression.

Fu P, Ibusuki M, Yamamoto Y, Hayashi M, Murakami K, Zheng S, Iwase H.

Breast Cancer Res Treat. 2011 Nov;130(1):307-17. doi: 10.1007/s10549-011-1605-0. Epub 2011 Jul 12.

PMID:
21748295
20.

Supplemental Content

Support Center